This page shows the latest dostarlimab news and features for those working in and with pharma, biotech and healthcare.
identify patients whose solid tumours are deficient in DNA mismatch repair (MMR) and who may benefit from GSK’s anti-PD-1 immunotherapy treatment Jemperli (dostarlimab-gxly).
GSK and iTeos are also planning to launch combination studies of the mAb with PD-1 inhibitor Jemperli (dostarlimab) in 2022.
The Food and Drug Administration (FDA) has approved Jemperli(dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved
GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. ... This data shows that dostarlimab may become an important new treatment
for multiple myeloma and dostarlimab for endometrial cancer.
GSK also highlighted the success of its new oncology medicine Dostarlimab, which is used in the treatment of advanced or recurrent endometrial cancer.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...